



## BioLineRx to Present at the 2013 BIO CEO & Investor Conference in New York on February 12th

January 31, 2013

JERUSALEM--(BUSINESS WIRE)--Jan. 31, 2013-- BioLineRx (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical development company, announced today that its Chief Executive Officer, Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer, Philip Serlin, will be presenting at the 2013 BIO CEO & Investor Conference in New York.

Dr. Savitsky and Mr. Serlin are scheduled to present at 2:00 P.M. EST on Tuesday, February 12th.

A live Webcast of the presentation will be available on the BioLineRx Website at <http://www.biolinerx.com/default.asp?pageid=63&itemid=155>. A replay will be available one hour after the presentation ends and will be accessible for three months following the presentation.

Investors or potential partners attending the conference that wish to meet with Dr. Savitsky or Mr. Serlin for a one-on-one meeting should contact the BIO Partnering Team at [biopartnering@bio.org](mailto:biopartnering@bio.org).

### About BioLineRx

BioLineRx is a publicly-traded biopharmaceutical development company. BioLineRx is dedicated to building a portfolio of products for unmet medical needs or with advantages over currently available therapies. BioLineRx's current portfolio consists of six clinical stage candidates: BL-1020 for schizophrenia is currently undergoing a Phase II/III study; BL-1040, for prevention of pathological cardiac remodeling following a myocardial infarction, which has been out-licensed to Ikaria Inc., is currently undergoing a pivotal CE-Mark registration trial; BL-5010 for non-surgical removal of skin lesions has completed a Phase I/II study; BL-1021 for neuropathic pain is in Phase I development, BL-7040 for treating inflammatory bowel disease (IBD) is currently undergoing a Phase II trial, and BL-8040 for treating acute myeloid leukemia (AML) and other hematological cancers has completed Phase I. In addition, BioLineRx has eight products in various pre-clinical development stages for a variety of indications, including central nervous system diseases, infectious diseases, cardiovascular and autoimmune diseases.

BioLineRx's business model is based on acquiring molecules mainly from biotechnological incubators and academic institutions. The Company performs feasibility assessment studies and development through pre-clinical and clinical stages, with partial funding from the Israeli Government's Office of the Chief Scientist (OCS). The final stage includes partnering with medium and large pharmaceutical companies for advanced clinical development (Phase III) and commercialization. For more information on BioLineRx, please visit [www.biolinerx.com](http://www.biolinerx.com).

Source: BioLineRx

KCSA Strategic Communications  
Garth Russell, 1-212-896-1250  
[grussell@kcsa.com](mailto:grussell@kcsa.com)

or  
Todd Fromer, 1-212-896-1250  
[tfromer@kcsa.com](mailto:tfromer@kcsa.com)

or  
Tsipi Haitovsky, Public Relations  
+972-3-6240871  
[tsipih@netvision.net.il](mailto:tsipih@netvision.net.il)